CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: The defucosylated human anti-CCR4 antibodies also demonstrated strong ADCC activity against Hodgkin’s lymphoma and cutaneous T-cell lymphoma cell lines (Figure 10f, g, Table S4c in File S1) and against the autologous Treg cells (Figure 10h).